MedTrace Logo

Safety and Performance of the SPINEVISION Hexanium ACIF in the Treatment of Cervical Spine Degenerative Disc Disease

NCT06155409 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 148

Last updated 2026-03-18

No results posted yet for this study

Summary

The goal of this observational study is to confirm the safety and efficacy of the Hexanium ACIF system in the treatment of skeletally mature patients suffering from degenerative disc disease (disease that occurs when the spinal disk breaks down) at the cervical spine level (C3-C7).

Part of their standard of care, participants will be questioned on their neck and arm pains, their disability and if they have encountered any adverse effects since the Hexanium ACIF system implant surgery. Those data will be collected up to twenty four (24) months after the Hexanium ACIF system implant surgery.

Conditions

  • Intervertebral Disc Degeneration

Interventions

DEVICE

Anterior cervical interbody fusion

Anterior cervical interbody fusion indicates a surgical approach in the cervical spine to fuse the discal space between two vertebrae. These are joined by removing the disc and placing a cage in its place to restore the vertebral height.

Sponsors & Collaborators

  • EVAMED

    collaborator OTHER

  • SPINEVISION SAS

    lead INDUSTRY

Principal Investigators

  • Patrice Lucas, Doctor · Centre Hospitalier de l'Europe

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-06
Primary Completion
2027-07-31
Completion
2027-07-31
FDA Device
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06155409 on ClinicalTrials.gov